Madrigal Pharmaceuticals (NASDAQ:MDGL) Insider Carole Huntsman Sells 910 Shares

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) insider Carole Huntsman sold 910 shares of the company’s stock in a transaction that occurred on Monday, January 26th. The shares were sold at an average price of $493.78, for a total value of $449,339.80. Following the transaction, the insider directly owned 9,122 shares in the company, valued at approximately $4,504,261.16. This represents a 9.07% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Carole Huntsman also recently made the following trade(s):

• On Friday, November 21st, Carole Huntsman sold 1,958 shares of Madrigal Pharmaceuticals stock. The shares were sold at an average price of $553.11, for a total value of $1,082,989.38.

Madrigal Pharmaceuticals Stock Performance

Shares of Madrigal Pharmaceuticals stock opened at $499.17 on Tuesday. The company has a quick ratio of 3.26, a current ratio of 3.44 and a debt-to-equity ratio of 0.54. The stock’s fifty day moving average is $558.07 and its two-hundred day moving average is $461.64. Madrigal Pharmaceuticals, Inc. has a 52 week low of $265.00 and a 52 week high of $615.00. The company has a market capitalization of $11.34 billion, a PE ratio of -38.37, a price-to-earnings-growth ratio of 4.66 and a beta of -1.00.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last issued its earnings results on Tuesday, November 4th. The biopharmaceutical company reported ($5.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.01) by ($3.07). Madrigal Pharmaceuticals had a negative net margin of 39.04% and a negative return on equity of 41.50%. As a group, analysts expect that Madrigal Pharmaceuticals, Inc. will post -23.47 earnings per share for the current year.

Hedge Funds Weigh In On Madrigal Pharmaceuticals

A number of large investors have recently bought and sold shares of the business. Baker BROS. Advisors LP boosted its position in Madrigal Pharmaceuticals by 8.4% during the 3rd quarter. Baker BROS. Advisors LP now owns 2,141,701 shares of the biopharmaceutical company’s stock valued at $982,313,000 after acquiring an additional 165,683 shares in the last quarter. William Blair Investment Management LLC raised its position in shares of Madrigal Pharmaceuticals by 17.6% in the 3rd quarter. William Blair Investment Management LLC now owns 411,802 shares of the biopharmaceutical company’s stock worth $188,877,000 after acquiring an additional 61,513 shares in the last quarter. Wellington Management Group LLP lifted its stake in shares of Madrigal Pharmaceuticals by 5,381.2% during the 3rd quarter. Wellington Management Group LLP now owns 404,455 shares of the biopharmaceutical company’s stock worth $185,507,000 after purchasing an additional 397,076 shares during the last quarter. Adage Capital Partners GP L.L.C. boosted its position in Madrigal Pharmaceuticals by 96.3% during the second quarter. Adage Capital Partners GP L.L.C. now owns 376,163 shares of the biopharmaceutical company’s stock valued at $113,842,000 after purchasing an additional 184,554 shares in the last quarter. Finally, Invesco Ltd. boosted its position in Madrigal Pharmaceuticals by 49.5% during the third quarter. Invesco Ltd. now owns 299,565 shares of the biopharmaceutical company’s stock valued at $137,398,000 after purchasing an additional 99,209 shares in the last quarter. Institutional investors own 98.50% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have commented on MDGL. Wolfe Research set a $579.00 target price on shares of Madrigal Pharmaceuticals in a research note on Tuesday, January 6th. Citigroup reissued an “outperform” rating on shares of Madrigal Pharmaceuticals in a research note on Tuesday, January 20th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Madrigal Pharmaceuticals in a research report on Thursday. Piper Sandler upped their target price on Madrigal Pharmaceuticals from $540.00 to $900.00 and gave the stock an “overweight” rating in a report on Friday, December 19th. Finally, JMP Securities set a $527.00 price target on Madrigal Pharmaceuticals in a research note on Wednesday, November 5th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $632.64.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for cardiovascular, metabolic and liver diseases. The company’s pipeline centers on novel, liver-directed agents designed to address significant unmet medical needs, with an emphasis on nonalcoholic steatohepatitis (NASH) and related metabolic disorders.

The lead product candidate, resmetirom (MGL-3196), is an orally administered, selective thyroid hormone receptor-β agonist in Phase 3 development for the treatment of NASH.